



Systemic Cancer Treatment in Pregnancy

Recommendations from the society for diagnosis and therapy of
haematological and oncological diseases

Publisher

DGHO Deutsche Gesellschaft für Hämatologie und
Medizinische Onkologie e.V.

Bauhofstr. 12
D-10117 Berlin

Executive chairwoman: Prof. Dr. med. Claudia Baldus

Phone: +49 (0)30 27 87 60 89 - 0

info@dgho.de

www.dgho.de

Contact person

Prof. Dr. med. Bernhard Wörmann
Medical superintendent

Source

www.onkopedia-guidelines.info

The information of the DGHO Onkopedia Web Site is not intended or implied to be a substitute for professional medical advice or medical care. The advice of a medical professional should always be sought prior to commencing any form of medical treatment. To this end, all component information contained within the web site is done so for solely educational purposes. DGHO Deutsche Gesellschaft für Hämatologie und Onkologie and all of its staff, agents and members disclaim any and all warranties and representations with regards to the information contained on the DGHO Web Site. This includes any implied warranties and conditions that may be derived from the aforementioned web site information.

Table of contents

1 Summary	2
2 Basics, epidemiology and pharmacological aspects	2
2.1 Incidence rates	2
2.2 Tumor entities and stages at diagnosis.....	3
2.3 Imaging diagnostics in women	4
2.4 Treatment modalities	4
2.5 Pharmacological features	5
2.5.1 Volume of distribution, metabolization, excretion.....	5
2.5.2 Placental penetration.....	5
2.5.3 Dose adjustment of antineoplastic agents in pregnant women	6
6 Therapy	6
6.1 Tumor entities	6
6.1.1 Acute leukemias	6
6.1.1.1 Acute myeloid leukemia (except acute promyelocytic leukemia)	7
6.1.1.2 Acute promyelocytic leukemia (AML M3/M3v)	7
6.1.1.3 Acute lymphoblastic leukemia	8
6.1.2 Chronic myeloid leukemia.....	8
6.1.3 Gliomas.....	9
6.1.4 Colorectal cancer	9
6.1.5 Lung cancer	10
6.1.6 Malignant lymphomas.....	10
6.1.6.1 Non-Hodgkin's lymphomas	10
6.1.6.2 Hodgkin's lymphoma	11
6.1.7 Breast cancer.....	12
6.1.8 Melanoma	13
6.1.9 Malignant ovarian tumors.....	14
6.1.10 Sarcomas	15
6.1.11 Cervical carcinoma	15
6.1.12 Other solid tumors	16
6.2 Supportive drug therapy during pregnancy.....	16
6.3 Other, non-pharmacological supportive measures	17
6.3.1 Fertility protection.....	17
6.4 Neonatal outcomes in patients and newborns.....	17
7 Registries	18
9 References	18
15 Authors' Affiliations	24
16 Disclosure of Potential Conflicts of Interest	24

Systemic Cancer Treatment in Pregnancy

Date of document: January 2025

Compliance rules:

- [Guideline](#)
- [Conflict of interests](#)

Authors: Georg Maschmeyer, Ralf Dittrich, Tanja Fehm, Inken Hilgendorf, Sibylle Loibl

1 Summary

- The stage of pregnancy and close cooperation in a multidisciplinary team are decisive for the therapeutic procedure. The risk-benefit analysis is particularly important for pregnant tumor patients.
- Ultrasound and magnetic resonance imaging are preferably used for diagnostic imaging.
- In the first trimester, an increased rate of subsequent malformations and miscarriages is to be expected as a consequence of systemic tumor therapy, so that systemic tumor therapy is not recommended.
- After systemic cancer therapy in the second trimester, a slightly increased rate of miscarriages, growth retardation, mental and physical underdevelopment has been documented. Systemic tumor therapy is possible here if indicated.
- With systemic tumor therapy in the third trimester, a largely comparable outcome with a normal course of pregnancy and development can be expected; if a premature birth should occur here, the corresponding problems arise as in pregnancies without malignant disease.
- Systemically administered tumor therapeutics are dosed according to the standard.
- Some agents such as tyrosine kinase inhibitors, *(V)EGF* antibodies, anti-hormonal substances or immune checkpoint inhibitors are contraindicated throughout the course of pregnancy. This has been addressed in the respective special sections of this guideline.
- The agents used for supportive therapy can also be used predominantly in the 2nd and 3rd trimester without any expected late effects for the newborn.
- If possible, an interval of 3 weeks between systemic therapy and delivery is recommended if drugs cause substantial myelosuppression.
- The goal is a normal delivery as for non-cancer patients; early induction of labor and section delivery (except for patients with cervical cancer) are discouraged.
- As a rule, normal early and late development of the children can be expected if the treatment recommendations are followed.
- Patient data should be entered into established registries.

2 Basics, epidemiology and pharmacological aspects

2.1 Incidence rates

According to currently available registry data, particularly from the International Network on Cancer, Infertility and Pregnancy (INCIP), 1-2 cases of cancer occur per 1,000 pregnancies [16, 26]. A report from Denmark includes 2426 cases from 1977-2006, with a significant increase from 1977-1986 to 1997-2006 [31]. A report from Norway includes 516 cases of preg-

nancy among 42,511 women with cancer from 1967-2002. Again, an increase in annual incidence was described [72]. Australian registry data of 1798 cases from 1994-2007 describe an increase in annual incidence from 1.12 to 1.91 per 1,000 pregnancies [48]. The increase in the number of cases is associated with the increasing mean age of pregnant women.

2.2 Tumor entities and stages at diagnosis

Reports from 2012-2018 are available from the International Network on Cancer, Infertility and Pregnancy (INCIP), which present the epidemiology of initial diagnoses of malignancies in pregnant women [6, 16, 27, 72].

The types of malignancies first diagnosed during pregnancy in 1170 women from 1996-2016 was reported as follows, see Table 1.

Table 1: Relative frequency of initial diagnoses of malignancies in pregnancy [27]

Malignant disease	Relative frequency (%)
Breast cancer	39
Cervical carcinoma	13
Lymphomas	10
Ovarian cancer	6
Leukemias	6
Melanoma	4
Gastrointestinal tumors	4
Thyroid carcinoma	3
Brain tumors	2
Other	12

These malignancies were also broken down according to the stage of disease at first diagnosis during pregnancy, see Table 2.

Table 2: Disease stages at the time of diagnosis during pregnancy [27]:

Stage	I	II	III	IV	Unknown
Breast cancer	15-20%	50%	20%	5-10%	3-5%
Cervical carcinoma	80%	10%	3%	4%	3%
Lymphoma	15%	50%	10%	10-12%	3-4%
Ovarian cancer	75%	5%	7%	3%	10%
Gastrointestinal tumors	3%	17%	20-25%	55%	2%
Melanoma	45%	10-15%	20-25%	5%	3%
Thyroid carcinoma	90-95%	3%	5%	-	-
Other	25-30%	5-6%	10-15%	30-35%	15%

A report from France that exclusively covers the occurrence of hematologic neoplasms with first diagnosis in pregnancy in 413 women in a total cohort of around 10 million pregnancies in the period from 2012-2022 [91] describes the frequencies shown in the following Table:

Table 3: Relative frequency of initial diagnoses of hematologic malignancies during pregnancy

Hematologic malignancy	Relative frequency (%)
Hodgkin's lymphoma	39.5
Acute leukemia	21.6
Aggressive B-cell non-Hodgkin's lymphoma	11.6
Myeloproliferative neoplasia	8.7
Myelodysplastic neoplasia or chronic myelomonocytic leukemia	5.1
Indolent non-Hodgkin's lymphoma	3.4
Other lymphomas	7.7
Other hematologic neoplasms	2.4

According to this study, there was no difference in the 5-year overall survival of women in whom the hematologic neoplasia was diagnosed during or after pregnancy.

2.3 Imaging diagnostics in women

In pregnancy, ultrasound and magnetic resonance imaging (MRI) without contrast enhancement are preferred imaging procedures due to their lack of ionizing radiation. However, concerns about possible harms to the fetus and mother may complicate decisions for both patients and clinicians. Based on two reviews [86, 96] that comprehensively discuss the use of imaging in pregnancy, the following assessments emerge.

Ultrasound: Ultrasound diagnostics have been used in pregnancy for decades and can be considered safe based on the results of a meta-analysis [93]. However, the theoretical risk of tissue heating and movement effects must be considered. The use of contrast sonography should be avoided unless the benefits clearly outweigh the possible risks of contrast agent administration.

MRI: A feared damage to the fetus in the first trimester due to MRI-induced tissue heating or clinically detectable hearing damage due to the noise in the 3 Tesla MRI could not be proven. Nevertheless, fetal exposure to loudness should be limited to 90 decibel. The use of gadolinium should be avoided, as it crosses the placental barrier, is excreted via the fetal kidneys into the amniotic fluid and can accumulate there. Gadolinium use during pregnancy has been reported to be associated with an increased risk of infiltrative skin diseases, rheumatologic and inflammatory diseases and early mortality of the child [92].

X-ray/computed tomography (CT): X-ray or CT imaging should only be ordered after a thorough risk-benefit assessment and in compliance with the fetal threshold dose of 50-100 mGy. In life-threatening situations or if an MRI is contraindicated, the benefit of a low dose CT may outweigh the risk. Fetal malformation, growth restriction, mental retardation or death are not expected with radiation levels used in diagnostic imaging, but the theoretical carcinogenic potential of ionizing radiation must be considered.

Mammography and sentinel lymph node staging: Mammography is considered safe in pregnancy, however, sensitivity may be reduced due to physiologically increased breast density. Sentinel lymph node staging with ⁹⁹technetium can also be performed during pregnancy. The radiation dose absorbed in the breast is less than 0.1-0.2 Gy.

2.4 Treatment modalities

An overview of the type of cancer treatment in 1170 pregnant women is provided by INCIP's work from 2018, see [Table 4](#).

Table 4: Treatment modalities in 1170 pregnant women with malignant diseases [27]

	n	No treatment	Surgery	Chemotherapy	Radiotherapy	Targeted or anti-hormonal therapy	Other
Breast cancer	462	116 (25%)	225 (49%)	248 (54%)	12 (3%)	7 (2%)	-
Cervical carcinoma	147	83 (56%)	32 (22%)	66 (58%)	2 (1%)	-	-
Lymphoma	113	41 (36%)	8 (7%)	66 (58%)	4 (4%)	18 (16%)	-
Ovarian cancer	88	23 (26%)	64 (73%)	21 (24%)	-	-	-
Leukemia	68	22 (32%)	-	23 (34%)	1 (1%)	7 (10%)	15 (22%)
Gastrointestinal tumor	49	19 (39%)	21 (43%)	16 (33%)	-	-	-
Melanoma	46	12 (26%)	33 (72%)	-	2 (4%)	-	-
Thyroid carcinoma	37	7 (19%)	30 (81%)	-	1 (3%)	-	-
Brain tumor	21	11 (52%)	10 (48%)	1 (5%)	1 (5%)	-	-
Other	139	57 (41%)	31 (22%)	17 (12%)	6 (4%)	1 (1%)	37 (27%)
Total	1170	391 (33%)	454 (39%)	429 (37%)	29 (2%)	33 (3%)	51 (4%)

2.5 Pharmacological features

Pharmacological data on the special features of systemic tumor therapy in pregnant women are naturally scarce. The approvals of chemotherapeutic agents, immunotherapeutic agents and molecularly targeted agents for antineoplastic therapy exclude their use in pregnant women, so that no systematic studies have been carried out on this topic. An overview can be found in [20]

2.5.1 Volume of distribution, metabolism, excretion

In the 6th-34th week of pregnancy, a volume expansion of 3-4 liters develops. The plasma volume increases by 1200 ml, the total erythrocyte volume by 300 ml, the placenta and the fetal circulation require an additional 2000 ml or more. The dilution effect reduces the albumin concentration in the blood [33]. Another consequence is increased renal clearance [51]. The activation of relevant enzymes of the cytochrome p450 system (*CYP 3A4*, *CYP 2C9*, *CYP 2A6*) and uridine diphosphate glucuronosyltransferase (*UGT*) results in faster hepatic metabolism, for example of taxanes and anthracyclines [15].

2.5.2 Placental penetration

Most chemotherapeutic agents are penetrating the placental barrier. This has been demonstrated for doxorubicin, daunorubicin, epirubicin, cyclophosphamide, paclitaxel (only minimally), 5-fluorouracil, capecitabine, oxaliplatin, irinotecan/SN38 (metabolite), vinblastine, cisplatin, carboplatin and cytarabine [14, 60, 69]. Transfer into the fetal circulation must be distinguished from placental transfer. Some of the information presented in Table 5 can be derived from sparse test results in humans and some data collected in monkeys, rabbits, rats and mice. An updated review was published in 2022 on the placental permeability of numerous systemically administered antineoplastic drugs [94].

Table 5: Placental permeability of chemotherapeutic agents [1, 60]

Substance class	Agent	Concentration in fetal compared to maternal circulation (%)
Anthracyclines	Doxorubicin	7.5
	Epirubicin	4.0
Taxanes	Docetaxel	0
	Paclitaxel	1.5
Alkylating agents	Cyclophosphamide	25.1
Antimetabolites	Cytarabine	56.7
	5-Fluorouracil	28.7
Vinca alkaloids	Vinblastine	18.5
Platinum derivatives	Cisplatin	31-65
	Carboplatin	57.5
Monoclonal antibodies	Trastuzumab	85
	Pertuzumab	30-40
	Bevacizumab	2-9
	Rituximab	150-328
Tyrosine kinase inhibitors	Gefitinib	20
	Erlotinib	25
	Imatinib	31
	Nilotinib	32

2.5.3 Dose adjustment of antineoplastic agents in pregnant women

Despite the relevant pharmacological and pharmacokinetic peculiarities in pregnant women, no substantial changes in dosage are recommended for systemic anticancer agents compared to their use in non-pregnant women. Chemotherapy dosing is based on current body weight or surface, and the area under the curve (AUC) for carboplatin dosing is unchanged compared to non-pregnant patients [16].

6 Therapy

6.1 Tumor entities

6.1.1 Acute leukemias

General symptoms such as fatigue and shortness of breath as well as blood count changes in the form of mild anemia or thrombocytopenia can occur both pregnancy-associated and in the early phase of acute leukemia. This carries the risk of delayed diagnosis and therefore requires particular clinical attention, especially as any delay in induction chemotherapy is associated with a reduction in the rate of complete remissions [78]. A treatment algorithm is shown in [Figure 1](#).

6.1.1.1 Acute myeloid leukemia (except acute promyelocytic leukemia)

Acute myeloid leukemia (AML) accounts for two-thirds of acute leukemias during pregnancy [78]. In addition to several reports from individual centers, each with a small number of patients, there are two literature reviews that have compiled data on AML in pregnant women from 1955-2013 [44] and 1969-2014 [23].

In 138 cases from the years 1955-2013, a standard combination of anthracycline and cytarabine was generally used for AML induction treatment (58%). The rate of complete remissions was 91%. The long-term survival of the mothers was 30%, with a low rate of risk-adapted consolidation therapies and allogeneic stem cell transplants in the affected patients. The rate of live births was 87%, with complications documented in 16%. Standard AML therapy during pregnancy was assessed as safe and effective, and early presentation of patients with high-risk AML for allogeneic stem cell transplantation is recommended [44].

In 85 cases of AML in pregnant women from 1969-2014, the results were broken down according to the start of chemotherapy in the 1st trimester (n = 8), 2nd trimester (n = 61) or 3rd trimester (n = 14). The CR rates were 100%, 81% and 67% in the 1st, 2nd and 3rd trimester, respectively. Fetal death and spontaneous abortion occurred in 37.5% vs 9.7% vs 0%. Remarkable were the rates of malformations or death after cytarabine + daunorubicin of 8.5%/6.4%, compared to 28.6%/12.5% after cytarabine + idarubicin [23]. In contrast to daunorubicin, idarubicin is more lipophilic, has a longer half-life, better placental permeability and a higher affinity for DNA, so that daunorubicin is considered the anthracycline of choice in pregnancy due to most extensive clinical experience and lower fetal toxicity [58].

Treatment of AML during pregnancy should be initiated immediately. As a successful pregnancy outcome seems unlikely after treatment start in the first trimester, reasons for or against termination of pregnancy should be discussed with the patient [4]. From the 2nd trimester, standard treatment with daunorubicin and cytarabine is recommended [4]. If AML has been diagnosed after the 32nd week of pregnancy, delivery should be attempted before initiating treatment in order to avoid the risk of chemotherapy-induced pancytopenia with a higher risk of infection and bleeding during the delivery phase [4] and to minimize fetal exposure to chemotherapeutic agents.

6.1.1.2 Acute promyelocytic leukemia (AML M3/M3v)

In acute promyelocytic leukemia (APL) diagnosed during pregnancy, there is a good chance of cure for the patient. All-trans retinoic acid (ATRA) and arsenic trioxide (ATO) have a high teratogenic potential. Options in the first trimester are a termination of pregnancy (attention to bleeding complications) or mono-chemotherapy with daunorubicin. After a termination of pregnancy, standard therapy with ATRA plus chemotherapy can be started immediately.

In the second and third trimester, there are no contraindications to combined treatment with ATRA and anthracyclines. A summary of all published cases of pregnant AML patients shows no increased maternal risk and no increased risk of malformations in the child. However, the rate of miscarriages, premature births and low birth weight newborns is increased. As these complications are associated with chemotherapy, the time to post-partum can be bridged by monotherapy with ATRA in pregnant women with APL at low or intermediate risk. For patients in the high-risk group, combination therapy with ATRA and anthracyclines (preferably daunorubicin) is indicated despite the associated risks [63]. The current guideline of the European LeukemiaNet [71] makes the same recommendations.

A systemic literature review [70] on pregnant women with APL shows a complete remission rate of 89% for 92 patients undergoing remission induction therapy with ATRA (32%) or ATRA +


chemotherapy (43%). Respiratory distress syndrome was present in 12 of 16 newborns with neonatal complications. In this regard, the ELN guideline [71] recommends the prophylactic administration of glucocorticoids, preferably prednisolone or methylprednisolone, in births before 36 weeks of gestation.

6.1.1.3 Acute lymphoblastic leukemia

Due to the rarer occurrence of acute lymphoblastic leukemia (ALL) compared to AML, treatment experience during pregnancy is limited. The application of methotrexate, which is usually given as part of ALL therapy, is contraindicated due to the high risk of the aminopterin syndrome [45, 58]. A prospective study showed a higher incidence of T-ALL in pregnant women compared to a control group of non-pregnant ALL patients (53.3% vs. 26.6%, $p = 0.034$) and also initially higher leukocyte counts (38.0 vs. $9.6 \times 10^9/l$, $p = 0.01$) [66]. This study reports on a total of 15 pregnant patients and 12 live births without subsequent impairment of the child development. Three patients underwent a termination of pregnancy in the first trimester and in three other patients the birth was induced in the last trimester after application of the pre-phase and induction therapy was started 3-4 days later. In addition, nine patients received pre-phase and induction therapy, five additionally received induction II and one patient also received two consolidations. In this study, pregnancy had no influence on overall survival and the recurrence rate [66]

The bispecific anti-CD3xCD19 antibody blinatumumab crosses the placenta in the mouse model [89] and should not be used during pregnancy.

Figure 1: Treatment algorithm for acute leukemias in pregnancy



Legend:

 = curative intended therapy

¹ WP = Week of pregnancy

² AML = Acute myeloid leukemia; APL = Acute promyelocytic leukemia; ALL = Acute lymphoblastic leukemia

³ "7 + 3" = Cytarabine + Daunorubicin

⁴ ATRA = All-trans-retinoic acid

⁵ MTX = Methotrexate

⁶ HSCT = Hematopoietic stem cell transplantation

⁷ GMALL = German Multicenter ALL study group

6.1.2 Chronic myeloid leukemia

Chronic myeloid leukemia (CML) accounts for 10% of all leukemias during pregnancy. During pregnancy, the use of tyrosine kinase inhibitors (TKIs) is contraindicated due to the teratogenic risk and an incidence of over 10% for serious events [1]. In patients with desire to have chil-

dren, the possibility of sperm cryopreservation should be discussed at the time of initial diagnosis [64]. For female CML patients desire to have children, individualized measures are required to allow the possibility of maintaining remission during pregnancy without the use of TKIs. Treatment interruption is only recommended in cases of stable molecular remission with a *BCR-ABL1* transcript level < 0.01%. In cases with a *BCR-ABL1* transcript level of 0.01-0.1%, therapy should initially be intensified in order to achieve a level below this threshold. Thus, patients undergoing imatinib therapy who are seeking pregnancy during a treatment break with a stable molecular remission should consider switching to a second-generation TKI in order to achieve a deeper and longer-lasting molecular remission [43]. If stable over 3-6 months, maintenance of remission over the course of pregnancy is likely. If molecular remission is lost during the treatment break in a pregnant woman, the time until delivery should be bridged without TKI resumption - if indicated, with interferon-alpha (IFN). The use of pegylated (PEG-)IFN is controversial and should be avoided, if possible, due to the accumulation of polyethylene glycol during pregnancy. If necessary, bridging cytoreduction with leukapheresis is an option in individual cases of significant leukocytosis. As imatinib and nilotinib have only been shown to have minimal placental permeability, the use of these substances after the 16th week of pregnancy can be considered in selected individual cases under very strict indications and risk-benefit analysis [1]. Dasatinib should generally not be used during pregnancy due to its placental permeability and high teratogenic risk. The use of bosutinib and newer TKIs is also contraindicated. Data on the outcome of different treatment regimens for CML during pregnancy have recently been compiled [22, 80].

6.1.3 Gliomas

There are only a few reports of pregnant women with primary brain tumors or brain metastases in the literature. Reliable epidemiologic data are lacking. Among 27 documented cases in the INCIP registry, 13 were diagnosed in the 2nd and 12 in the 3rd trimester. Neurosurgical interventions (n = 8), radiotherapy (n = 7) and chemotherapy (n = 3) were used therapeutically. All 21 children born were described as healthy with no apparent impairment, also after a follow-up of up to 25 years [74]. Case series from individual centers [76] as well as a systematic literature review [73] indicate that pregnancy can lead to a poorer clinical course of gliomas, without, however, having a significant impact on the prognosis [73]. Evidence-based guidelines on the clinical procedure for pregnant women with primary brain tumors or brain metastases are not available.

For pregnant women in the second and third trimester, current data support the recommendation to use the same standard treatment protocols as for non-pregnant women.

6.1.4 Colorectal cancer

In accordance with the age distribution of patients with colorectal cancer (CRC), only a few properly documented cases of CRC in pregnant women are available in the literature. A literature search from 2017 revealed 119 case reports (53% colon, 44% rectum, 3% multiple), with first diagnosis in the 2nd and 3rd trimester in 88%. Of 82 patients whose treatment was described, around 10% received chemotherapy during pregnancy [67]. The INCIP registry published 41 well-documented cases, including 27 colon and 14 rectal carcinomas [47]. Advanced stages were found in 73% of patients. Surgery was performed in 51% and chemotherapy in 29% of pregnant women. The birth of healthy children was achieved in 33 of the 41 patients (80.5%), with section delivery in 21 cases. According to these registry data and a single center report [40], no significant difference was found in the prognosis of pregnant patients with CRC compared to non-pregnant women.

No reliable data are available on the selection of antineoplastic substances or treatment protocols that are suitable for the drug treatment of pregnant women with CRC. Fluoropyrimidines such as 5-FU and capecitabine, as well as irinotecan and oxaliplatin, mainly administered in the standard protocols FOLFOX and FOLFIRI, appear to be commonly used in the second and third trimester without any specific toxicities being found in the newborns [69]. *EGFR* antibodies such as cetuximab and panitumumab as well as substances directed against *VEGF(R)* such as bevacizumab, aflibercept or ramucirumab are contraindicated, as are multikinase inhibitors directed also against *VEGFR* (e.g., regorafenib).

6.1.5 Lung cancer

The largest published collection to date of all cases of non-small cell lung cancer (NSCLC) in pregnant women documented in the literature and in a single institution includes 77 patients [75]. It is estimated that 85% of all lung cancers in pregnant women are NSCLC [59]. Only 9 cases of lung cancer were reported from the INCIP registry in 2013, all of which were diagnosed at advanced stages [18]. The risk of metastasis to the placenta or fetus is reported to be up to 26% of 44 cases evaluated [12].

There are no evidence-based treatment recommendations for pregnant women with lung cancer. In view of the generally advanced stages of the disease, curative primary resections are not very promising. Chemotherapy using carboplatin and paclitaxel is justified from the beginning of the 2nd trimester, see chapter 6.1.6.1. Since an above-average rate of molecular aberrations such as *ALK* rearrangements and activating *EGFR* mutations is to be expected in pregnant women with NSCLC [25], it is obvious to consider the use of molecularly targeted tumor therapies. Individual case reports are available [17], from which the justification for individual treatment decisions can be derived. Reliable study results are not available. Comprehensive registry data on the use of immune checkpoint inhibitors (ICI) against *PD1*, *PD-L1* or *CTLA4* show no higher overall rates of negative effects on pregnancy, fetuses or newborns than systemically administered chemotherapeutic agents, but an increased rate of premature births after the use of combined checkpoint blockade against *PD1* and *CTLA4* has been reported [84]. Nevertheless, the use of ICI in pregnant women cannot be recommended, especially as no long-term follow-up studies are yet available.

6.1.6 Malignant lymphomas

- Malignant lymphomas are the fourth most common cancer diagnosis in pregnancy. Hodgkin's and non-Hodgkin's lymphomas (NHL) account for 5% and 6% respectively of all pregnancy-related cancers [30]. A treatment algorithm is shown in Fig. 2.

6.1.6.1 Non-Hodgkin's lymphomas

The most comprehensive data by now on NHL in pregnant women was published from the INCIP registry in 2021 [56]. Of a total of 80 patients, 57 had diffuse large B-cell lymphomas. One patient's pregnancy was terminated, 46 women received systemic lymphoma therapy (usually R-CHOP). All 46 patients with and all 10 patients without systemic lymphoma therapy during pregnancy had a live birth. One of the children who had been exposed to chemotherapy *in utero* was found to be malformed. Among the 23 women with other NHL, 20 carried their pregnancy to term, 19 also had a live birth. The treatment outcome of patients with NHL who received systemic lymphoma therapy during their pregnancy, followed up for more than 10 years, was comparable to that of non-pregnant patients. This was also observed in a large registry study from Australia and New Zealand including 41 women with lymphoma during pregnancy [81]. It was concluded that pregnant women with NHL should generally receive the same

systemic treatment as non-pregnant women [56]. This was also published as a recommendation in a consensus guideline [52].

As a special aspect, it was pointed out that prednisolone and methylprednisolone should be given preference over other glucocorticoids, if glucocorticoid therapy is indicated, due to their lower placental permeability and pronounced placental metabolism. A review of the use of new substances in lymphoma therapy [54] shows that data are only available for the application of rituximab in the 2nd and 3rd trimester [79], which can justify its use. Close blood count monitoring of the newborn should be considered after treatment with rituximab up to 6 months of age. The Onkopedia guideline on diffuse large-cell non-Hodgkin's lymphoma (DLBCL), updated in 2022, contains specific recommendations for the treatment of pregnant patients with DLBCL [65] (extract):


- If an aggressive lymphoma occurs in the first trimester, termination of pregnancy is recommended, as chemotherapy carried out during the organogenesis phase carries a high risk of malformations. The risk is low in the second and third trimester.
- The R-CHOP protocol is suitable as a standard treatment regimen. Antimetabolites (e.g., MTX) must not be used due to the risk of fetal CNS damage.
- If the lymphoma occurs in late pregnancy and is not very aggressive, treatment can be postponed to post delivery.

6.1.6.2 Hodgkin's lymphoma

In 24 patients with Hodgkin's lymphoma (HL) who were treated with systemic chemotherapy during pregnancy (usually ABVD), the outcome of the pregnancy was documented in 20 cases. There were 2 premature births, however, 2 of 11 patients who did not receive lymphoma therapy during pregnancy also had a premature birth [34].

While the use of ABVD for the treatment of HL in the first trimester is controversial, its use in the 2nd and 3rd trimester can be considered an appropriate and safe treatment option [36]. Accordingly, ABVD is the most commonly used regimen for HL therapy during pregnancy, with 241 cases now reported [30, 89]. There is only one case report on the use of nivolumab during pregnancy in the relapse situation of treatment-refractory HL with subsequent engraftment syndrome after autologous stem cell transplantation post partum. The concentration of nivolumab in the mother's blood was higher than in the umbilical cord blood and could not be detected in the placenta [35]. The use of brentuximab vedotin is contraindicated during pregnancy.

Figure 2: Treatment algorithm for malignant lymphoma in pregnancy



Legend:

= curative intended therapy

¹ WP = Week of pregnancy

² DLBCL = Diffuse large B-cell lymphoma

³ ABVD = Doxorubicin/Bleomycin/Vinblastin/Dacarbazine

⁴ R-CHOP = Rituximab/Cyclophosphamide/Doxorubicin/Vincristine/Prednisolone

⁵ Wait-and-see approach (if possible), local radiotherapy (head/neck/thorax/extremities), CHOP, rituximab; recommendation by a multidisciplinary tumor conference

6.1.7 Breast cancer

Breast cancer accounts for 39% of all malignancies in pregnant women, see chapter 2.2. Accordingly, specific publications available today are extensive, providing detailed data on diagnostics and therapy, specified for surgical, radiotherapeutic, chemotherapeutic, endocrine and immunotherapeutic treatment procedures, in comparison to other cancers in pregnant women. Long-term studies on children who were exposed to chemotherapy in utero for the treatment of their mother's breast cancer show no negative effects of this therapy on their state of health [85].

A comparison of the prognosis of pregnant (n = 662) vs. non-pregnant (n = 2081) patients with breast cancer was published from the INCIP registry, which shows no significant difference in disease-free (78% vs. 85%) and overall survival (90% vs. 94%) after 3 years [8]. These registry data also indicate that surgical interventions, chemotherapy and local radiotherapy were administered in approximately comparable proportions. Both endocrine and *HER2*-targeted therapies are not recommended during pregnancy according to current knowledge [10, 61].


While surgical procedures are also permitted in the 1st trimester, potentially associated with a higher risk of miscarriage (for sentinel node staging, only technetium is recommended due to allergic reactions described), systemic chemotherapy may only be administered from the 2nd trimester (from week 13 of pregnancy) [38, 42]. Anthracyclines (doxorubicin and epirubicin), in combination with cyclophosphamide, and taxanes (paclitaxel and docetaxel, but not nab-paclitaxel) are, as with other chemotherapies in pregnancy (see above), indicated as in non-pregnant women [83]. Carboplatin is used on a case-by-case basis according to the current AGO recommendation [2]. Thus, standard regimens such as AC/EC followed by paclitaxel or the additional use of carboplatin in triple-negative carcinomas can be applied from the 2nd trimester onwards in the same way as in non-pregnant patients. Dose-dense administration of AC/EC (q2w), followed by weekly paclitaxel, is also accepted, if indicated, combined with the appropriate supportive measures [53]; 5-fluorouracil or methotrexate should not be used in pregnant women.

Endocrine therapies (tamoxifen, fulvestrant or aromatase inhibitors) should not be administered to pregnant women.

Molecularly targeted therapies such as *PARP* inhibitors, *CDK4/6* inhibitors, lapatinib, neratinib, tucatinib, *PI3 kinase* inhibitors or *mTOR* inhibitors are contraindicated in pregnant women, as are monoclonal antibodies (e.g., bevacizumab, trastuzumab, pertuzumab, *PD1/PD-L1* inhibitors or sacituzumab govitecan). More rarely applied substances such as capecitabine, eribulin or vinorelbine, for which there are no reliable data on their use in pregnant women, should be avoided.

A treatment algorithm is shown in [Figure 3](#).

Figure 3: Treatment algorithm for breast cancer during pregnancy



Legend:

= curative intended therapy

¹ WP = Week of pregnancy

² Chemotherapy, immunotherapy/immunoconjugates, anti-hormonal therapy, molecularly targeted therapy

³ Including dose-dense protocols

⁴ Individual case recommendation by multidisciplinary tumor conference

6.1.8 Melanoma

Melanoma is relatively common in pregnant women worldwide. For example, the incidence in Australia (New South Wales) in 2008 was 52 cases per 100,000 pregnancies [13], but in line with the epidemiology of malignant melanomas, it is far lower in other regions of the world, for example 3-5/100,000 pregnancies in Europe [68]. The INCIP registry has reported 60 documented cases, including 14 in stage III and 16 in stage IV (27% in relapse) [28]. An analysis of 1406 pregnant melanoma patients from the Californian cancer registry showed no negative impact of pregnancy on overall survival compared to more than 10,000 non-pregnant women in this registry [87]. Therapeutically, mainly locoregional surgery and, in individual cases, local radiotherapy are used, while systemic therapeutics such as *BRAF/MEK*-targeted tyrosine kinase inhibitors or immune checkpoint inhibitors should generally be avoided due to their incalculable risks for the fetus, despite isolated favorable case reports [9]. For further information on immune checkpoint inhibitors, see chapter 6.1.5 (lung cancer).

Localized melanomas in particular do not have a significantly different prognosis in pregnant women, as shown by case-control studies with up to 185 documented patients [49]. The surgical literature contains specific recommendations on the practical surgical procedures for pregnant women with melanoma [24].

As a special feature of malignant melanomas, it is recommended to look carefully for placental metastases after delivery, which have been described as well as fetal metastasis [3, 46].

6.1.9 Malignant ovarian tumors

The incidence of malignant ovarian tumors in pregnant women is reported to be approximately 0.2-3.8 per 100,000 pregnancies [5]. Of the unclear adnexal tumors occurring in 0.2-2% of all pregnancies, 1-6% represent a malignant neoplasm [37].

Standard chemotherapeutic treatment with carboplatin and paclitaxel has proven to be safe for pregnant women in the second and third trimester [21, 77]. As *VEGF* (vascular endothelial growth factor) is of central importance for embryonic and fetal development and for the regulation of amniotic fluid, the use of the *VEGF* inhibitor bevacizumab is contraindicated.

Local radiotherapy of malignant ovarian tumors is obsolete in pregnant women.


INCIP data indicate that the treatment outcome is similar to that of non-pregnant patients and that the prognosis depends on the tumor stage [37].

The current recommendations are as follows:

Surgical interventions in the early stages of a malignant ovarian tumor should preferably be performed from the 16th week of pregnancy. Chemotherapy can be administered from the 2nd trimester using the same regimens as for non-pregnant women. If neoadjuvant chemotherapy is indicated for locally advanced disease, carboplatin and paclitaxel can be used for epithelial ovarian cancer or cisplatin with etoposide and bleomycin for non-epithelial malignancies [5]. Updated recommendations on the diagnostic, surgical and drug treatment of pregnant women with ovarian cancer were published in 2024 by the European Society of Gynecologic Oncology (ESGO) together with the European Society of Medical Oncology (ESMO) and the European Society of Pathology (ESP) [88].

A treatment algorithm is shown in Figure 4.

Figure 4: Treatment algorithm for ovarian cancer in pregnancy



Legend:

= Curative intended therapy

¹ WP = Week of pregnancy

² Recommendation by multidisciplinary tumor conference

6.1.10 Sarcomas

The largest data collection to date comprises a retrospective analysis of 13 patients (4 with osteosarcoma and 9 with soft tissue sarcoma) who received anthracyclines and / or ifosfamide for sarcoma therapy [57]. A median of 3 treatment cycles were administered starting at a gestational age of 19.5 +/- 4 weeks. Pregnancy complications occurred in 10/13 (76.9%) cases. Fetal growth retardation was described in 6/13 (46.2%) of cases. The median gestational age at the time of preterm delivery, which occurred in all cases, was 30.8 +/- 3.8 weeks. The majority (66.7%) of the newborns required intensive care. Abortion occurred in 4 patients. These patients had previously received treatment with doxorubicin and ifosfamide starting at 15.5 weeks, while all other patients started treatment significantly later (median 21 weeks). The median disease-free survival was 62 months and three patients with soft tissue sarcoma died of the disease within 4 months of diagnosis.

6.1.11 Cervical carcinoma


In a cohort study of the INCIP registry, 132 pregnant women and 256 non-pregnant women with cervical cancer and comparable patient characteristics from the years 1990-2012 were analyzed [41]. 14.4% of the pregnant women were in FIGO stage IA, 47.0% in stage IB1, 18.9% in stage IB2 and 19.7% in stages II-IV. In 26.5%, tumor therapy could be postponed until delivery, 17.4% were treated with primary surgery, 16.7% received neoadjuvant chemotherapy and 12.9% had a premature delivery. There was no difference in progression-free survival between pregnant and non-pregnant women. In a long-term study of 21 pregnant women with cervical carcinoma from 1985-2000, a 5-year survival rate of 82% was described, again with no significant difference to comparable non-pregnant patients [39].

An international consensus conference developed detailed treatment recommendations in 2019 [5]. Neoadjuvant chemotherapy using carboplatin and paclitaxel is recommended for pregnant women with cervical carcinoma in stages IA2-IB3 beyond the 22nd week of pregnancy for whom treatment cannot be postponed until delivery.

The AWMF S3 guideline on cervical carcinoma 2022 recommends treating pregnant women with cervical carcinoma similarly to non-pregnant women, with neoadjuvant, platinum-based chemotherapy recommended from the 2nd trimester onwards [11]. All current recommendations support a caesarean section as the delivery method of choice. There are no randomized studies on maternal outcomes depending on the mode of delivery. In the case of microinvasive carcinomas, case-control studies and retrospective analyses show no deterioration in prognosis as a result of spontaneous parturition. In the S3 guideline on cervical carcinoma, spontaneous delivery is only recommended for microinvasive carcinomas if an *in sano* resection was previously performed as part of a conization. Spontaneous delivery is not recommended in the presence of a microinvasive carcinoma with R1 resection or without conization due to the risk of bleeding and the risk of lymphovascular dissemination [11].

A treatment algorithm for cervical cancer in pregnancy is shown in [Figure 5](#).

Figure 5: Treatment algorithm for cervical cancer during pregnancy



Legend:

= curative intended therapy

¹ WP = Week of pregnancy (time limit according to the S3 guideline of the AWMF 2022 [11])

² A European consensus conference [5] differentiates again between the 12th and 22nd week of pregnancy

³ FIGO = International Federation of Gynecology and Obstetrics, version from 2018

⁴ Recommendation by multidisciplinary tumor conference

6.1.12 Other solid tumors

No substantial data on pregnant patients is available for numerous other solid malignancies such as head and neck carcinomas, pancreatic carcinomas, neuroendocrine tumors, urothelial carcinomas, renal cell carcinomas or hepatobiliary cancer.

A collection of 13 pregnant women with gastric carcinomas published from the INCIP registry [55] does not allow any recommendations to be derived for the oncological care of these patients.

Although thyroid carcinomas represent 3% of malignant neoplasms in pregnant women (see above), they are almost exclusively treated without systemic antineoplastic agents. Pregnant patients with thyroid cancer do not have a different prognosis compared to non-pregnant patients [62].

6.2 Supportive drug therapy during pregnancy

According to the recommendations of an international consensus conference with INCIP participation [52], both metoclopramide and 5-HT₃ antagonists [82] can be used safely for antiemetic therapy in pregnant women undergoing chemotherapy. No data are available on aprepitant and its use in pregnancy is cautioned against (<https://www.drugs.com/mtm/aprepitant.html>).

For antibiotic therapy in pregnant women undergoing chemotherapy, many of the commonly used antibacterial agents are non-critical according to current knowledge, while aminoglycosides, sulfonamides, trimethoprim, fluoroquinolones, amoxicillin-clavulanic acid and tetracyclines should be avoided [4]. If systemic antifungal therapy is necessary, amphotericin B preparations should be preferred, see [ONKOPEDIA Invasive fungal infections - therapy](#) (Guideline in German language).

The use of recombinant G-CSF is not associated with any unusual complications in pregnant patients [19].


Low-molecular-weight heparins can be used prophylactically and therapeutically [52].

Prednisolone and methylprednisolone are to be preferred for glucocorticoid therapy, see Chapter 6.1.6.1.

Bisphosphonates should not be used in pregnant women. However, there are data from the literature that describe no significant harm to newborns after unknowingly using bisphosphonates during pregnancy [29, 50].

An algorithm for the use of supportive therapy measures in pregnant cancer patients is shown in Figure 6.

Figure 6: Algorithm for the use of supportive drug therapy in pregnant cancer patients



Legend:

¹ G-CSF = granulocyte colony-stimulating factor

6.3 Other, non-pharmacological supportive measures

6.3.1 Fertility protection

In the case of desire to have children, fertility preservation options for oncological patients should be discussed with the patient in the same way as when the oncological disease is diagnosed outside the time of pregnancy. Recommendations for fertility preservation have been published for patients under the age of 25 [90]. In addition to conservative surgical treatment of cervical cancer, other options include cryopreservation of ovarian tissue, which can be removed during a caesarean section, for example, see Onkopedia Fertility Preservation (<https://www.onkopedia.com/de/onkopedia/guidelines/fertilitaetserhalt/@@guideline/html/index.html>).

6.4 Neonatal outcomes in patients and newborns

According to a meta-analysis from 2016, systemic tumor therapy in the 2nd or 3rd trimester (after the 14th week) of pregnancy (carried out according to the premises stated in this guideline) is not associated with significant problems in fetal development, meaning that early termination of the pregnancy is not necessary [32]. In a long-term follow-up of the INCIP registry, no adverse effects on cognitive, cardiac or general development were observed in 129 children born after maternal chemotherapy during pregnancy compared to a "matched control" group [7]. An analysis of cognitive and behavioral development in a total of 151 nine-year-old children whose mothers had cancer during pregnancy, also published by the INCIP group, showed no deviations from normal findings in the 109 children who were exposed to systemic tumor therapy in utero [95]. It is emphasized that regardless of the presence of cancer or cancer treatment, premature birth has unfavorable effects, so that pregnant cancer patients should aim for a normal duration of pregnancy and normal delivery [7].

7 Registries

It is recommended that data on the treatment and progression of tumors in pregnant women be entered into established registries. For breast cancer: BCP registry of the German Breast Group (www.gbg.de), for all other carcinomas: INCIP registry (<https://cancerinpregnancy.org>).

9 References

1. Abruzzese E, Aureli S, Bondanini F et al. Chronic myeloid leukemia and pregnancy: when dreams meet reality. State of the art, management and outcome of 41 cases, nilotinib placental transfer. *J Clin Med* 2022;11:1801. DOI:10.3390/jcm11071801
2. AGO Empfehlungen Brustkrebs - Spezielle Situationen 2024. https://www.ago-online.de/fileadmin/ago-online/downloads/_leitlinien/kommission_mamma/2024/einzeldateien/ago_2024d_15_brustkrebs_spezielle_situationen
3. Alexander A, Samlowski WE, Grossman D et al. Metastatic melanoma in pregnancy: risk of transplacental metastases in the infant. *J Clin Oncol* 2003;21:2179-2186. DOI:10.1200/JCO.2003.12.149
4. Ali S, Jones GL, Culligan DJ et al. Guidelines for the diagnosis and management of acute myeloid leukaemia in pregnancy. *Br J Haematol* 2015;170:487-495. DOI:10.1111/bjh.13554
5. Amant F, Berveiller P, Boere IA et al. Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting. *Ann Oncol* 2019;30:1601-1612. DOI:10.1093/annonc/mdz228
6. Amant F, Loibl S, Neven P, Van Calsteren K. Breast cancer in pregnancy. *Lancet* 2012;379:570-579. DOI:10.1016/S0140-6736(11)61092-1
7. Amant F, Vandenbroucke T, Verheecke M et al. Pediatric outcome after maternal cancer diagnosed during pregnancy. *N Engl J Med* 2015;373:1824-1834. DOI:10.1056/NEJ-Moa1508913
8. Amant F, Nekljudova V, Maggen C et al. Outcome of breast cancer patients treated with chemotherapy during pregnancy compared with non-pregnant controls. *Eur J Cancer* 2022;170:54-63. DOI:10.1016/j.ejca.2022.04.014
9. Andrikopoulou A, Korakiti AM, Apostolidou K, Dimopoulos MA, Zagouri F. Immune checkpoint inhibitor administration during pregnancy: a case series. *ESMO Open* 2021;6:100262. DOI:10.1016/j.esmoop.2021.100262
10. AWMF S3 Leitlinie Mammakarzinom 2021. https://www.awmf.org/uploads/tx_szleitlinien/032-045oll_s3_mammakarzinom_2021-07
11. AWMF S3 Leitlinie Zervixkarzinom 2022. https://register.awmf.org/assets/guidelines/032-033oll_s3_diagnostik_therapie_nachsorge_zervixkarzinom_2022-03
12. Azim HA Jr, Peccatori FA, Pavlidis N. Lung cancer in the pregnant woman: to treat or not to treat, that is the question. *Lung Cancer* 2010;67:251-256. DOI:10.1016/j.lungcan.2009.10.006
13. Bannister-Tyrrell M, Roberts CL, Hasovits C, Nippita T, Ford JB. Incidence and outcomes of pregnancy-associated melanoma in New South Wales 1994-2008. *Aust N Z J Obstet Gynaecol* 2015;55:116-122. DOI:10.1111/ajo.12279
14. Benoit L, Mir O, Vialard F, Berveiller P. Cancer during pregnancy: a review of preclinical and clinical transplacental transfer of anticancer agents. *Cancers* 2021;13:1238. DOI:10.3390/cancers13061238

15. Berveiller P, Selleret L, Mir O. Drug selection and dosing in pregnant cancer patients: insights from clinical pharmacokinetics. *Ann Oncol* 2014;25:1869-1870. DOI:10.1093/annonc/mdu376
16. Boere I, Lok C, Vandenbroucke T, Amant F. Cancer in pregnancy: safety and efficacy of systemic therapies. *Curr Opin Oncol* 2017;29:328-334. DOI:10.1097/CCO.0000000000000386
17. Boudy AS, Grausz N, Selleret L et al. Use of tyrosine kinase inhibitors during pregnancy for oncogenic-driven advanced non-small cell lung carcinoma. *Lung Cancer* 2021;161:68-75. DOI:10.1016/j.lungcan.2021.09.001
18. Boussios S, Han SN, Fruscio R et al. Lung cancer in pregnancy: report of nine cases from an international collaborative study. *Lung Cancer* 2013;82:499-505. DOI:10.1016/j.lungcan.2013.09.002
19. Boxer LA, Bolyard AA, Kelley ML et al. Use of granulocyte colony-stimulating factor during pregnancy in women with chronic neutropenia. *Obstet Gynecol* 2015;125:197-203. DOI:10.1097/AOG.0000000000000602
20. Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. *Lancet Oncol* 2004;5:283-291. DOI:10.1016/S1470-2045(04)01466-4
21. Cardonick E, Bhat A, Gilmandyar D, Somer R. Maternal and fetal outcomes of taxane chemotherapy in breast and ovarian cancer during pregnancy: case series and review of the literature. *Ann Oncol* 2012;23:3016-3023. DOI:10.1093/annonc/mds170
22. Castillo DR, Park D, Mehta A, Kaur S, Nguyen A, Akhtari M. Outcomes of the pregnancies with chronic myeloid leukemia in the tyrosine kinase inhibitor era and literature review. *Hematol Rep* 2022;14:45-53. DOI:10.3390/hematolrep14010008
23. Chang A, Patel S. Treatment of acute myeloid leukemia during pregnancy. *Ann Pharmacother* 2015;49:48-68. DOI:10.1177/1060028014552516
24. Crisan D, Treiber N, Kull T, Widschwendter P, Adolph O, Schneider LA. Surgical treatment of melanoma in pregnancy: a practical guideline. *J Dtsch Dermatol Ges* 2016;14:585-593. DOI:10.1111/ddg.12996
25. Dagogo-Jack I, Gainor JF, Porter RL et al. Clinicopathologic features of NSCLC diagnosed during pregnancy or the peripartum period in the era of molecular genotyping. *J Thorac Oncol* 2016;11:1522-1528. DOI:10.1016/j.jtho.2016.05.031
26. Dalmartello M, Negri E, La Vecchia C et al. Frequency of pregnancy-associated cancer: a systematic review of population-based studies. *Cancers* 2020;12:1356. DOI:10.3390/cancers12061356
27. De Haan J, Verheecke M, Van Calsteren K et al. Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients. *Lancet Oncol* 2018;19:337-346. DOI:10.1016/S1470-2045(18)30059-7
28. De Haan J, Lok CA, de Groot CJ et al. Melanoma during pregnancy: a report of 60 pregnancies complicated by melanoma. *Melanoma Res* 2017;27:218-223. DOI:10.1097/CMR.0000000000000327
29. Djokanovic N, Klieger-Grossmann C, Koren G. Does treatment with bisphosphonates endanger the human pregnancy? *J Obstet Gynaecol Can* 2008;30:1146-1148. DOI:10.1016/S1701-2163(16)34026-34029
30. Dunleavy K, McLintock C. How I treat lymphoma in pregnancy. *Blood* 2020;136:2118-2124. DOI:10.1182/blood.2019000961
31. Eibye S, Kjær SK, Mellekjær L. Incidence of pregnancy-associated cancer in Denmark, 1977-2006. *Obstet Gynecol* 2013;122:608-617. DOI:10.1097/AOG.0b013e3182a057a2

32. Esposito S, Tenconi R, Preti V, Groppali E, Principi N. Chemotherapy against cancer during pregnancy: A systematic review on neonatal outcomes. *Medicine (Baltimore)* 2016;95:e4899. DOI:10.1097/MD.0000000000004899
33. Evans SR, Sarani B, Bhanot P, Feldman E. Surgery in pregnancy. *Curr Probl Surg* 2012;49:333-388. DOI:10.1067/j.cpsurg.2012.02.003
34. Evens AM, Advani R, Press OW et al. Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. *J Clin Oncol* 2013;31:4132-4139. DOI:10.1200/JCO.2013.49.8220
35. Evens AM, Brandt JS, Peer CJ et al. Checkpoint inhibitor immunotherapy during pregnancy for relapsed-refractory Hodgkin lymphoma. *Am J Hematol* 2022;97:833-838. DOI:10.1002/ajh.26527
36. Eyre TA, Lau IJ, Mackillop L, Collins GP. Management and controversies of classical Hodgkin lymphoma in pregnancy. *Br J Haematol* 2015;169:613-630. DOI:10.1111/bjh.13327
37. Fruscio R, de Haan J, Van Calsteren K, Verheecke M, Mhallem M, Amant F. Ovarian cancer in pregnancy. *Best Pract Res Clin Obstet Gynaecol* 2017;41:108-117. DOI:10.1016/j.bpobgyn.2016.09.013
38. Gentilini O, Cremonesi M, Toesca A et al. Sentinel lymph node biopsy in pregnant patients with breast cancer. *Eur J Nucl Med Mol Imaging* 2010;37:78-83. DOI:10.1007/s00259-009-1217-7
39. Germann N, Haie-Meder C, Morice P et al. Management and clinical outcomes of pregnant patients with invasive cervical cancer. *Ann Oncol* 2005;16:397-402. DOI:10.1093/annonc/mdi084
40. Grass F, Spindler BA, Naik ND et al. Oncological outcome of peripartum colorectal carcinoma-a single-center experience. *Int J Colorectal Dis* 2019;34:899-904. DOI:10.1007/s00384-019-03278-2
41. Halaska MJ, Uzan C, Han SN et al. Characteristics of patients with cervical cancer during pregnancy: a multicenter matched cohort study. An initiative from the International Network on Cancer, Infertility and Pregnancy. *Int J Gynecol Cancer* 2019;29:676-682. DOI:10.1136/ijgc-2018-000103
42. Han SN, Amant F, Cardonick EH et al. Axillary staging for breast cancer during pregnancy: feasibility and safety of sentinel lymph node biopsy. *Breast Cancer Res Treat* 2018;168:551-557. DOI:10.1007/s10549-017-4611-z
43. Hochhaus A, Baccarani M, Silver RT et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. *Leukemia* 2020;34:966-984. DOI:10.1038/s41375-020-0776-2
44. Horowitz NA, Henig I, Henig O, Benyamini N, Vidal L, Avivi I. Acute myeloid leukemia during pregnancy: a systematic review and meta-analysis. *Leuk Lymphoma* 2018;59:610-616. DOI:10.1080/10428194.2017.1347651
45. Hyoun SC, Običan SG, Scialli AR. Teratogen update: methotrexate. *Birth Defects Res A Clin Mol Teratol* 2012;94:187-207. DOI:10.1002/bdra.23003
46. Khazzaka A, Rassy E, Sleiman Z, Boussios S, Pavlidis N. Systematic review of fetal and placental metastases among pregnant patients with cancer. *Cancer Treat Rev* 2022;104:102356. DOI:10.1016/j.ctrv.2022.102356
47. Kocián P, de Haan J, Cardonick EH et al. Management and outcome of colorectal cancer during pregnancy: report of 41 cases. *Acta Chir Belg* 2019;119:166-175. DOI:10.1080/00015458.2018.1493821

48. Lee YY, Roberts CL, Dobbins T et al. Incidence and outcomes of pregnancy-associated cancer in Australia, 1994-2008: a population-based linkage study. *BJOG* 2012;119:1572-1582. DOI:10.1111/j.1471-0528.2012.03475.x
49. Lens MB, Rosdahl I, Ahlbom A et al. Effect of pregnancy on survival in women with cutaneous malignant melanoma. *J Clin Oncol* 2004;22:4369-4375. DOI:10.1200/JCO.2004.02.096
50. Levy S, Fayed I, Taguchi N et al. Pregnancy outcome following in utero exposure to bisphosphonates. *Bone* 2009;44:428-430. DOI:10.1016/j.bone.2008.11.001
51. Lindheimer MD, Davison JM, Katz AI. The kidney and hypertension in pregnancy: twenty exciting years. *Semin Nephrol* 2001;21:173-189. DOI:10.1053/snep.2001.20937
52. Lishner M, Avivi I, Apperley JF et al. Hematologic malignancies in pregnancy: management guidelines from an international consensus meeting. *J Clin Oncol* 2016;34:501-508. DOI:10.1200/JCO.2015.62.4445
53. Loibl S, Schmidt A, Gentilini O et al. Breast cancer diagnosed during pregnancy: adapting recent advances in breast cancer care for pregnant patients. *JAMA Oncol* 2015;1:1145-1153. DOI:10.1001/jamaoncol.2015.2413
54. Luttwak E, Gurevich-Shapiro A, Azem F et al. Novel agents for the treatment of lymphomas during pregnancy: a comprehensive literature review. *Blood Rev* 2021;49:100831. DOI:10.1016/j.blre.2021.100831
55. Maggen C, Lok CA, Cardonick E et al. Gastric cancer during pregnancy: A report on 13 cases and review of the literature with focus on chemotherapy during pregnancy. *Acta Obstet Gynecol Scand* 2020;99:79-88. DOI:10.1111/aogs.13731
56. Maggen C, Dierickx D, Cardonick E et al. Maternal and neonatal outcomes in 80 patients diagnosed with non-Hodgkin lymphoma during pregnancy: results from the International Network of Cancer, Infertility and Pregnancy. *Br J Haematol* 2021;193:52-62. DOI:10.1111/bjh.17103
57. Miller D, Livingston JA, Park Y et al. Pregnancy outcomes related to the treatment of sarcomas with anthracyclines and/or ifosfamide during pregnancy. *Cancer Med* 2022;11:3471-3478. DOI:10.1002/cam4.4707
58. Milojkovic D, Apperley JF. How I treat leukemia during pregnancy. *Blood* 2014;123:974-984. DOI:10.1182/blood-2013-08-283580
59. Mitrou S, Petrakis D, Fotopoulos G, Zarkavelis G, Pavlidis N. Lung cancer during pregnancy: A narrative review. *J Adv Res* 2016;7:571-574. DOI:10.1016/j.jare.2015.12.004
60. Miyamoto S, Yamada M, Kasai Y, Miyauchi A, Andoh K. Anticancer drugs during pregnancy. *Jpn J Clin Oncol* 2016;46:795-804. DOI:10.1093/jjco/hyw073
61. NCCN Guideline Breast Cancer 6.2024. https://www.nccn.org/professionals/physician_gls/pdf/breast
62. Nobre GM, Tramontin MY, Treisman N et al. Pregnancy has no significant impact on the prognosis of differentiated thyroid cancer. *Arch Endocrinol Metab* 2021;65:768-777. DOI:10.20945/2359-3997000000413
63. ONKOPEDIA, Akute Promyelozytenleukämie (APL), 11/2022, <https://www.onkopedia.com/s/SGLHH4>
64. ONKOPEDIA, Chronische Myeloische Leukemie (CML), 06/2018, <https://www.onkopedia.com/s/UBKBAH>
65. ONKOPEDIA, Diffus-großzelliges B-Zell-Lymphom (DLBCL), 01/2024, <https://www.onkopedia.com/s/NDK411>

66. Parovichnikova EN, Troitskaya VV, Gavrilina OA et al. The outcome of Ph-negative acute lymphoblastic leukemia presenting during pregnancy and treated on the Russian prospective multicenter trial RALL-2009. *Leuk Res* 2021;104:106536. DOI:10.1016/j.leukres.2021.106536
67. Pellino G, Simillis C, Kontovounisios C et al. Colorectal cancer diagnosed during pregnancy: systematic review and treatment pathways. *Eur J Gastroenterol Hepatol* 2017;29:743-753. DOI:10.1097/MEG.0000000000000863
68. Ribero S, Longo C, Dika E et al. Pregnancy and melanoma: a European-wide survey to assess current management and a critical literature overview. *J Eur Acad Dermatol Venereol* 2017;31:65-69. DOI:10.1111/jdv.13722
69. Rogers JE, Dasari A, Eng C. The treatment of colorectal cancer during pregnancy: cytotoxic chemotherapy and targeted therapy challenges. *Oncologist* 2016;21:563-570. DOI:10.1634/theoncologist.2015-0362
70. Santolaria A, Perales A, Montesinos P, Sanz MA. Acute promyelocytic leukemia during pregnancy: a systematic review of the literature. *Cancers* 2020;12:968. DOI:10.3390/cancers12040968
71. Sanz MA, Fenaux P, Tallman MS et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. *Blood* 2019;133:1630-1643. DOI:10.1182/blood-2019-01-894980
72. Stensheim H, Møller B, van Dijk T, Fosså SD. Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study. *J Clin Oncol* 2009;27:45-51. DOI:10.1200/JCO.2008.17.4110
73. Verheecke M, Halaska MJ, Lok CA et al. Primary brain tumors, meningiomas and brain metastases in pregnancy: report on 27 cases and review of literature. *Eur J Cancer* 2014;50:1462-1471. DOI:10.1016/j.ejca.2014.02.018
74. van Westrhenen A, Senders JT, Martin E, DiRisio AC, Broekman MLD. Clinical challenges of glioma and pregnancy: a systematic review. *J Neurooncol* 2018;139:1-11. DOI:10.1007/s11060-018-2851-3
75. Yang L, He YT, Kang J et al. Clinical features and intervention timing in patients with pregnancy-associated non-small-cell lung cancer. *J Thorac Dis* 2021;13:4125-4136. DOI:10.21037/jtd-21-234
76. Yust-Katz S, de Groot JF et al. Pregnancy and glial brain tumors. *NeuroOncol* 2014;16:1289-1294. DOI:10.1093/neuonc/nou019
77. Zheng X, Zhu Y, Zhao Y, Feng S, Zheng C. Taxanes in combination with platinum derivatives for the treatment of ovarian cancer during pregnancy: A literature review. *Int J Clin Pharmacol Ther* 2017;55:753-760. DOI:10.5414/CP202995
78. Zhu D, Tang D, Chai X, Zhang G, Wang Y. Acute leukemia in pregnancy: a single institutional experience with 21 cases at 10 years and a review of the literature. *Ann Med* 2021;53:567-575. DOI:10.1080/07853890.2021
79. Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. *Blood* 2011;117:1499-1506. DOI:10.1182/blood-2010-07-295444
80. Chelysheva E, Apperley J, Turkina A et al. Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry. *Leukemia* 2024;38:788-795. DOI:10.1038/s41375-024-02183-0
81. Di Ciaccio PR, Mills G, Shipton MJ et al. The clinical features, management and outcomes of lymphoma in pregnancy: A multicentre study by the Australasian Lymphoma Alliance. *Br J Haematol* 2023;201:887-896. DOI:10.1111/bjh.18727

82. Dormuth CR, Winqvist B, Fisher A et al. Comparison of pregnancy outcomes of patients treated with ondansetron vs alternative antiemetic medications in a multinational, population-based cohort. *JAMA Netw Open* 2021;4:e215329. DOI:10.1001/jamanetworkopen.2021.5329
83. Ferrigno Guajardo AS, Vaca-Cartagena BF, Mayer EL et al. Taxanes for the treatment of breast cancer during pregnancy: an international cohort study. *J Natl Cancer Inst* 2024;116:239-248. DOI:10.1093/jnci/djad219
84. Gougis P, Hamy AS, Jochum F et al. Immune checkpoint inhibitor use during pregnancy and outcomes in pregnant individuals and newborns. *JAMA Netw Open* 2024;7:e245625. DOI:10.1001/jamanetworkopen.2024.5625
85. Greiber IK, Viuff JH, Storgaard L et al. Long-term morbidity and mortality in children after in utero exposure to maternal cancer. *J Clin Oncol* 2022;40:3975-3984. DOI:10.1200/JCO.22.00599
86. Jha P, Pöder L, Glanc P et al. Imaging cancer in pregnancy. *Radiographics* 2022;42:1494-1513. DOI:10.1148/rg.220005
87. Kiuru M, Li Q, Zhu G et al. Melanoma in women of childbearing age and in pregnancy in California, 1994-2015: a population-based cohort study. *J Eur Acad Dermatol Venereol* 2022;36:2025-2035. DOI:10.1111/jdv.18458
88. Ledermann JA, Matias-Guiu X, Amant F et al. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease. *Ann Oncol* 2024;35:248-266. DOI:10.1016/j.annonc.2023.11.015
89. Mills GS, Chadwick V, Tang C et al. Immunochemotherapy for life-threatening haematological malignancies in pregnancy: a systematic review of the literature and cross-sectional analysis of clinical trial eligibility. *Lancet Haematol* 2023;10:e458-e467. DOI:10.1016/S2352-3026(23)00059-5
90. Mulder RL, Font-Gonzalez A, Hudson MM et al. Fertility preservation for female patients with childhood, adolescent, and young adult cancer: recommendations from the PanCare-LIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. *Lancet Oncol* 2021;22:e45-e56. DOI:10.1016/S1470-2045(20)30594-5
91. Pinson P, Boussaid I, Decroocq J et al. Maternal and obstetric outcomes in women with pregnancy-associated haematological malignancies: an observational nationwide cohort study. *Lancet Haematol* 2024;11:e850-e861. DOI:10.1016/S2352-3026(24)00288-6
92. Ray JG, Vermeulen MJ, Bharatha A, Montanera WJ, Park AL. Association between MRI exposure during pregnancy and fetal and childhood outcomes. *JAMA* 2016;316:952-961. DOI:10.1001/jama.2016.12126
93. Torloni MR, Vedmedovska N, Merialdi M et al. Safety of ultrasonography in pregnancy: WHO systematic review of the literature and meta-analysis. *Ultrasound Obstet Gynecol* 2009;33:599-608. DOI:10.1002/uog.6328
94. Triarico S, Rivetti S, Capozza MA et al. Transplacental passage and fetal effects of antineoplastic treatment during pregnancy. *Cancers (Basel)* 2022;14:3103. DOI:10.3390/cancers14133103
95. Van Assche IA, Huis In 't Veld EA, Van Calsteren K et al. Cognitive and behavioral development of 9-year-old children after maternal cancer during pregnancy: a prospective multi-center cohort study. *J Clin Oncol* 2023;41:1527-1532. DOI:10.1200/JCO.22.02005
96. Wiles R, Hankinson B, Benbow E, Sharp A. Making decisions about radiological imaging in pregnancy. *BMJ*. 2022 Apr 25;377:e070486. DOI:10.1136/bmj-2022-070486

15 Authors' Affiliations

Prof. Dr. Ralf Dittrich

Universitätsklinikum Erlangen
Frauenklinik
Universitätsstraße 21/23
91054 Erlangen
Ralf.Dittrich@uk-erlangen.de

Prof. Dr. Tanja Fehm

Universitätsklinikum Düsseldorf
Frauenklinik
Moorenstr. 5
40225 Düsseldorf
Tanja.Fehm@med.uni-duesseldorf.de

apl. Prof. Dr. med. Inken Hilgendorf

Universitätsklinikum Jena
KIM II
Abt. für Hämatologie und Internistische Onkologie
Am Klinikum 1
07747 Jena
inken.hilgendorf@med.uni-jena.de

Prof. Dr. med. Sibylle Loibl

German Breast Group und
J. W. Goethe Universität Frankfurt/Main
GBG Forschungs GmbH
Martin Behaim Strasse 12
63263 Neu-Isenburg
Sibylle.Loibl@gbg.de

Prof. Dr. med. Georg Maschmeyer

Deutsche Gesellschaft für Hämatologie
und Medizinische Onkologie (DGHO)
Onkopedia-Koordinator
Bauhofstr. 12
10117 Berlin
maschmeyer@dgho.de

16 Disclosure of Potential Conflicts of Interest

according to the [rules of DGHO, OeGHO, SGH+SSH, SGMO](#)

Author	Employer ¹	Consulting / Expert opinion ²	Shares / Funds ³	Patent / Copyright / License ⁴	Fees ⁵	Funding of scientific research ⁶	Other financial relations ⁷	Personal relationship with authorized representatives ⁸
Dittrich, Ralf	Universitätsklinikum Erlangen, Kinderwunschzentrum Dr. Jürgen Krieg MVZ in Amberg, CPF-Cryoprotection GmbH in Erlangen	Yes StMGP-Bayern, Ferring, Vitrolife	Yes Amgen, BB-Biotech, CPF-Cryoprotection, Cryolofe, Siemens-Healthiners	No	Yes Ferring, MSD-Organon, Merck-Serono, Lilly	Yes Beckman-Coulter, Roche	No	No
Fehm, Tanja	Universitätsklinikum Düsseldorf	Yes Nur indirekt (als Dienstaufgabe, keine direkte Zuwendung): Roche, Novartis, Daichii Sankyo, MSD, Eisai, Pfizer, AstraZeneca	No	No	Yes Onkowissen, Springer-Verlag, Elsevier-Verlag, MedConcept, FOMF	No	Yes Reisekostenerstattung Daichii Sankyo, Roche	No
Hilgendorf, Inken	Universitätsklinikum Jena Klinik für Innere Medizin II Abt. für Hämatologie und Internistische Onkologie Am Klinikum 1 07747 Jena	No	No	No	Yes Honorare für Vortrags- und Schulungstätigkeiten von AbbVie, Medlearning, Medac, Novartis, Takeda	No	Yes Reisekostenerstattung durch Amgen, Beigene, Janssen-Cilag, JAZZ-Pharmaceuticals, Medac, Neovii	No
Loibl, Sibylle	GBG Forschungs GmbH, Neu-Isenburg	Yes Abbvie, Amgen, AstraZeneca, BMS, Celgene, DSI, Eirgenix, Eisai, GSK, Gilead, Lilly, Merck, Novartis, Pfizer, Pierre Fabre, Relay Therapeutics, Roche, Sanofi, Seagen; BEIGENE; Bicycle; Biontech; Jazzpharma; Stemline	No	Yes EP14153692.0 EP21152186.9 EP18209672 EP24210258 VM Scope GmbH	Yes Abbvie, Amgen, AstraZeneca, BMS, Celgene, DSI, Eirgenix, Eisai, GSK, Gilead, Lilly, Merck, Novartis, Pfizer, Pierre Fabre, Relay Therapeutics, Roche, Sanofi, Seagen; BEIGENE; Bicycle; Biontech; Jazzpharma; Stemline	Yes Abbvie, AstraZeneca, Celgene, DSI, Gilead, Molecular Health, Novartis, Pfizer, Roche; Stemline Menarini,	No	No

Author	Employer ¹	Consulting / Expert opinion ²	Shares / Funds ³	Patent / Copyright / License ⁴	Fees ⁵	Funding of scientific research ⁶	Other financial relations ⁷	Personal relationship with authorized representatives ⁸
Maschmeyer, Georg	Aktuell: DGHO e.V. (Honorarvertrag) Charité Universitätsmedizin Berlin Bis 31.3.2022: Klinikum Ernst von Bergmann, Potsdam	No	No	No	No	No	No	No

Legend:

¹ - Current employer, relevant previous employers in the last 3 years (institution/location).

² - Activity as a consultant or expert or paid participation in a scientific advisory board of a company in the health care industry (e.g., pharmaceutical industry, medical device industry), a commercially oriented contract research organization, or an insurance company.

³ - Ownership of business shares, stocks, funds with participation of companies of the health care industry.

⁴ - Relates to drugs and medical devices.

⁵ - Honoraria for lecturing and training activities or paid authors or co-authorships on behalf of a company in the health care industry, a commercially oriented contracting institute or an insurance company.

⁶ - Financial support (third-party funds) for research projects or direct financing of employees of the institution by a company in the health care industry, a commercially oriented contract institute or an insurance company.

⁷ - Other financial relationships, e.g., gifts, travel reimbursements, or other payments in excess of 100 euros outside of research projects, if paid by an entity that has an investment in, license to, or other commercial interest in the subject matter of the investigation.

⁸ - Personal relationship with an authorized representative(s) of a healthcare company.